Public Health Agency of Canada Expert Panel on mpox in Canada: Members

About membership

The Public Health Agency of Canada Expert Panel on Mpox in Canada is composed of a diverse membership to ensure a range of scientific, clinical and public health perspectives and advice. The panel is chaired by the Public Health Agency of Canada (PHAC).

Members include scientists, researchers and experts who are external to the Canadian federal government and scientists and experts from within the federal government. Technical participants from federal departments and agencies will be invited to PHAC expert panel meetings on topics relevant to their areas of expertise.

Questions regarding affiliations and interests

Affiliations and interests disclosed by extramural expert panel members were reviewed by the Chair and Secretariat. Disclosed interests are summarized below. In no instance was a declared interest assessed such that it precluded participation in the expert panel.

Members are expected to review their affiliations and interests against meeting agenda items and advise the Chair and Secretariat if they see a potential cause for concern regarding the integrity and objectivity of their participation. Based on this review, they will decide, if necessary, to limit a member's participation in all or part of the meeting agenda. They will inform the members of this decision.

Summaries are provided for each of the expert panel members based on the following questions:

1. Direct financial interests

Do you, your spouse or common-law partner, or dependent family member have any direct financial interests that are of relevance to the mandate of the expert panel, including current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares, or bonds?

2. Indirect financial interests

Within the past five years, have you, your spouse or common-law partner, or dependent family member received payment for work done or being done, or financial support, from a party that has an interest in the mandate of the expert panel? Include past employment, contracts or consulting, research support, personal education grants, contributions, fellowships, sponsorships, and honoraria for teaching, speaking, or writing engagements.
Within the past five years, have you, your spouse or common-law partner, or dependent family member received materials, discounted products, gifts, or other benefits, or attended conferences or meetings where all or part of the travel and accommodation costs were provided by a party that has an interest in the mandate of the expert panel?
Within the past five years, have any of the organizations where you, your spouse or common-law partner, or dependent family member are currently employed or participate in internal decision making (for example: as a board member or as an executive or non-executive director) received grants or other funding from a party that has an interest in the mandate of the expert panel?

3. Intellectual interests

Within the past five years, have you provided any formal advice or opinion to industry; a Canadian federal, provincial, or municipal government; a foreign government; or a non-government organization on a matter of relevance to the mandate of the expert panel? Include, for example, expert testimony or acting as witness (full or part-time), participation on an advisory body etc.
Have you ever made public a statement (e.g. speeches, lobbying) or publicly stated a point of view (including in scientific papers, articles, journals, or other publications, or on other websites) on issues of relevance to the expert panel's mandate?
Do you currently have any professional or volunteer affiliations (such as membership in professional/scientific societies, trade associations, or in public interest, or advocacy groups) that may have an interest in the mandate and work of this expert panel?

4. Other affiliations and interests

Do you, your spouse or common-law partner, or dependent family member have any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable apprehension or grounds for concern regarding the integrity and objectivity of your participation in this expert panel?
Are you active on social media on issues relevant to this expert panel?

Expert panel member responses on affiliations and interests

Summary of responses

Summary of responses
Name	Summary of Responses
Sapha Barkati Associate Professor, Infectious Diseases and Medical Microbiology and Educational Director of the J.D MacLean Centre for Tropical and Geographic Medicine, McGill University	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	Yes	Yes	Yes	No	No
	Comments Member of the Quebec Immunization Committee providing formal advice for mpox vaccine use. Delivered public statements on topics related to mpox in televised interviews and journal articles. Member of the ASTMH (American Society of Tropical Medicine and Hygiene), the ISTM (International Society of Travel Medicine) and chair of its migrant health interest group.
Isaac Bogoch Associate Professor, Department of Medicine, University of Toronto	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	Yes	No	Yes	Yes	Yes	No	No	Yes
	Comments Former consultant with BlueDot, a social benefit corporation that tracks emerging infectious diseases. Received research grants from the Canadian Institutes of Health Research as primary investigators on COVID-19 epidemiology, schistosomiasis diagnostics, and HIV prevention. Advised the Weapons Threat Reduction Program at Global Affairs Canada on issues pertaining to health security. Author of peer-reviewed scientific articles on mpox. Delivered public statements on mpox and other infectious diseases in media interviews and social media. Member of the Committee to Advise on Tropical Medicine and Travel (CATMAT).
Nicholas Brousseau Associate Clinical Professor, Laval University	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	Yes	No	No	No	No
	Comments Member of the Quebec Immunization Committee and the National Advisory Committee on Immunization.
David Evans Virologist, Department of Medical Microbiology and Immunology, University of Alberta	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	Yes	No	Yes	Yes	Yes	Yes	No	No
	Comments Provides consulting services as required for Tonix Pharmaceuticals related to poxvirus-based vaccines. Held research contracts with Emergent BioSolutions and Tonix Pharmaceuticals, and is a co-applicant on several Canadian Institutes of Health Research (CIHR) applications concerning monkeypox virus. Past member of research laboratory with a recently licensed patented derivative of vaccinia virus to Pnuvax Inc. Author of peer-reviewed scientific articles on mpox. Member of the Canadian Society for Virology as well as the American Society for Virology.
Judith Fafard Microbiologist, Medical Director, Quebec Public Health Laboratory, Institut national de santé publique du Québec	1.	2a.	2b.	2c.	3a.	3b.	3c.	4.	4b.
	Yes	Yes	Yes	No	Yes	No	No	No	No
	Comments Employed by the Institut National de santé publique du Québec. Recipient of funding for research collaborations on the clinical effectiveness of tecovirimat and asymptomatic detection of mpox. Recipient of speaker fees for scientific talks and presentations on mpox (Fédération des médecins spécialistes du Québec). Provided formal advice on vaccine use and prevention and control for mpox to a provincial government.
Mark Gilbert Associate Professor School of Population & Public Health, UBC Clinical Prevention Services, BCCDC	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	No	No	No	No	No
Daniel Grace Associate Professor, Dalla Lana School of Public Health, University of Toronto	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	No	No	Yes	No	No
	Comments An affiliated researcher with the Community-Based Research Centre (CBRC) on issues related to mpox.
Jessica Hopkins Chief Health Protection and Emergency Preparedness Officer, Public Health Ontario	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No
	Comments Makes decisions related to public health response to mpox as part of role at Public Health Ontario. Recipient of travel funding to attend meetings as member of the CIHR Institute Advisory Board on Population and Public Health. Provides advice and recommendations to government ministries on various communicable diseases, including mpox, in the context of current role with Public Health Ontario. Member at large of the Ontario Medical Association, Section of Public Health and Preventative Medicine and member of the Canadian Medical Association.
Jason Kindrachuck Associate Professor, Medical Microbiology & Infectious Diseases, Max Rady College of Medicine, University of Manitoba	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	Yes	No	No	Yes	Yes	Yes	No	No
	Comments Recipient of grant funding for mpox research from the Canadian Institutes of Health Research. Provided expert advice on mpox to the Office of Pandemic Preparedness and Response Policy, The White House as well as an expert witness for public health recommendation litigation. Author of scientific publications on mpox. Delivered public statements on mpox and other infectious diseases on social media. Member of the Advisory Committee on Human Pathogens and Toxins, the World Health Organization Guideline Development Group, the World Health Organization (WHO) Health Emergencies (WHE) Infection Prevention and Control (IPC) Hub, and the Scientific Advisory Board – Canadian Consortium of Academic Biosafety Level 3 Laboratories (CCABL3).
Marina Klein Professor of Medicine Research Director, Division of Infectious Diseases/Chronic Viral Illnesses Service, McGill University	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	Yes	Yes	No	Yes	Yes	No	No
	Comments Recipient of drug/placebo Tecorvirimat (TPOXX) from Siga for the conduct of a randomized clinical trial in mpox. The Research Institute of the McGill University Health Centre is the recipient of a contribution agreement with PHAC supporting the TPOXX clinical trial (since Aug 2022 to March 31, 2025). National Director of the CIHR PanCanadian HIV/AIDS & STBBI Clinical Trials Network. Author of scientific publications on mpox. Delivered public statements on mpox as a member of a media roundtable. Member of the International AIDS Society and the Infectious Diseases Society of America as well as the WHO clinical management and mpox living atlas advisory group.
Joanne Langley Professor of Pediatrics and Community Health and Epidemiology and GSK-CIHR Chair in Pediatric Vaccinology, Dalhousie University; and Head, Division of Pediatric Infectious Diseases, IWK Health	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	No	No	No	No	No
Michael Libman Director, J.D. MacLean Centre for Tropical and Geographic Medicine, McGill University	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	Yes	Yes	Yes	No	No	No
	Comments Recipient of funding from a variety of sources as principal investigator of the GeoSentinel Network. Chair of the Committee to Advise on Tropical Medicine and Travel (CATMAT). Provided expert advice on mpox to the Public Health Agency of Canada and the Travellers' Health Branch of the CDC. Author of scientific publications on mpox.
Mark Loeb Professor, Pathology & Molecular Medicine, McMaster University	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	Yes	No	No	No	No	No
	Comments Recipient of MVA smallpox vaccine from Bavarian Nordic for a randomized trial.
Carmen Logie Professor, Factor-Inwentash Faculty of Social Work, University of Toronto	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	No	Yes	No	No	No
	Comments Author of an article on mpox stigma.
Allison McGeer Infectious Disease Consultant and Senior Clinician Investigator, Sinai Health; and Professor, Department of Laboratory Medicine and Pathobiology, Dalla Lana School of Public Health, University of Toronto	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	No	Yes	Yes	No	No	No
	Comments Delivered public statements on topics related to mpox and environmental contamination, in media interviews and journal articles. Member of a provincial governmental mpox clinical advisory committee to the office of the Chief Medical Officer of Health of Ontario.
Rita Shahin Associate Medical Officer of Health, Toronto Public Health; and Adjunct Professor, Dalla Lana School of Public Health, University of Toronto	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	Yes	No	No	No	No	Yes	Yes	No	No
	Comments Currently employed by Toronto Public Health and acts as a media spokesperson on issues related to mpox. Delivered public statements on topics related to mpox, in media interviews and journal articles. Member of the Ontario Medical Association.
Darrell Tan Clinician-Scientist, Division of Infectious Diseases, St. Michael's Hospital; and Associate Professor, Faculty of Medicine, University of Toronto	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	No	No	Yes	Yes	Yes	No	No	No
	Comments Recipient of funding from CIHR, PHAC and the University of Toronto for mpox projects. Delivered public statements on topics related to mpox, in media interviews and journal articles. Member of the NACI Mpox working group and expert advisor to the Ontario Chief Medical Officer of Health.
Sharon Walmsley Professor of Medicine, Department of Medicine, University of Toronto; and Senior Scientist, Toronto General Hospital Research Institute	1.	2a.	2b.	2c.	3a.	3b.	3c.	4a.	4b.
	No	Yes	No	No	No	Yes	Yes	No	No
	Comments Recipient of Tecovirimat for a randomized controlled trial. Author of several peer-reviewed journal articles on mpox. Co-director of the Canadian HIV clinical trials network.

Page details

2025-01-30

Language selection

Search